year
111Category: | Pharmaceuticals and Biochemicals/Antineoplastics agents |
|
|
CAS NO: | 877399-52-5 | ||
EC NO: | |||
Molecular Formula: | C21H22Cl2FN5O | ||
Molecular Weight: | 450.3367 | ||
Specification: | 99% | ||
InChI: | InChI=1/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1 | ||
Product description: English name :Crizotinib Molecular formula : C21H22Cl2FN5O Molecular weight : 450.34 cas:877399-52-5 Properties: white crystallized powder Quality standard :Enterprise standard Main application: Treat abnormal anaplastic lymphoma kinase (ALK) gene rearranged end-stage non-small cell lung cancer |
|||
Synonyms: | (5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanamine;3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine;3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine;Crizotinib;PF2341066;2-pyridinamine, 3-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1h-pyrazol-4-yl]-;PF-02341066; | ||
Molecular Structure: |